No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 24 of the 33 quarters in the window, leaving 9 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 34
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:21:17.123Z. Latest historical point 2026-03-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T18:21:17.123Z. Latest historical point 2024-03-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T18:21:17.123Z. Latest historical point 2024-03-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T18:21:17.123Z. Latest historical point 2024-03-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T18:21:17.123Z. Latest historical point 2024-03-25. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Equillium, Inc. (EQ) stock was $1.44 as of Oct 6, 2026, 2:20 PM EDT, down 0.69% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -3.3% · 3-year avg +26.7%/yr · 5-year avg -27.0%/yr
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient.
Biotechnology · La Jolla, CA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.05
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.04
vs Estimate
$-0.06
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1EQ | $91.05M | $1.44 | -0.69% | -3.34% | -26.99% | N/A | N/A |
| 2BMEA | $91.46M | $1.26 | -2.69% | -39.39% | -36.56% | N/A | vs EQ |
| 3RLYB | $90.24M | $17.00 | +0.62% | +271.55% | -35.80% | N/A | vs EQ |
| 4PMVP | $90.13M | $1.69 | -5.06% | +23.49% | -43.17% | N/A | vs EQ |
| 5ICCC | $89.84M | $9.93 | +1.86% | +54.20% | +0.65% | +2.46% | vs EQ |
| 6PARK | $92.47M | $20.48 | -2.89% | N/A | N/A | N/A | vs EQ |
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$8.56
+494.1% upside
Low
$4.00
Current
$1.44
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.06 | $-0.05 | $-0.04 | 6 |
| Quarter ending Dec 2026 | $-0.07 | $-0.06 | $-0.05 | 6 |
| Quarter ending Mar 2027 | $-0.06 | $-0.06 | $-0.06 | 2 |
| Quarter ending Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.22 | $-0.21 | $-0.19 | 7 |
| FY 2027 | $-0.34 | $-0.23 | $-0.19 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $15.58M | $15.58M | $15.58M | 5 |
| FY 2027 | $16.52M | $16.52M | $16.52M | 9 |
